Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 8/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609920 | 0.80 | NR1H2 (0.41) | NR1H2MEN1KMT2APREPSRC | |
| SCHEMBL31457995 | 0.74 | PREP (0.37) | NR1H2MEN1KMT2APREPATM | |
| SCHEMBL1639634 | 0.72 | NR1H2 (0.42) | NR1H2MEN1KMT2APREPCHRM2 | |
| SCHEMBL2227084 | 0.72 | NR1H2 (0.42) | NR1H2MEN1KMT2APREPCHRM2 | |
| SCHEMBL24821656 | 0.72 | NR1H2 (0.42) | NR1H2MEN1KMT2APREPCHRM2 | |
| SCHEMBL31457968 | 0.70 | PREP (0.36) | NR1H2MEN1KMT2APREPATM | |
| SCHEMBL31457937 | 0.70 | NR1H2 (0.40) | NR1H2MEN1KMT2APREPCHRM2 | |
| SCHEMBL31457946 | 0.70 | PREP (0.38) | NR1H2MEN1KMT2APREPATM | |
| SCHEMBL71904 | 0.69 | NR1H2 (0.45) | NR1H2ATMCHRM2CHRM1CHRM3 | |
| SCHEMBL283443 | 0.69 | NR1H2 (0.45) | NR1H2ATMCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | NR1H2 1197/4885MEN1 1353/4885KMT2A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.